Protalix BioTherapeutics PLX
NYSE PLX
$2.42 +0.04 (+1.68%)
As of: Aug 21, 2026 · 11:18 AM EDT

Protalix BioTherapeutics (PLX) Short term Debt (2016 - 2024)

Protalix BioTherapeutics (PLX) posted quarterly Short term Debt of $20.4 million for Q2 2024, little changed quarter-over-quarter from $20.4 million in Q1 2024.

Protalix BioTherapeutics (PLX) Short term Debt (2016 - 2024) Analysis & Trends

Protalix BioTherapeutics' Short term Debt history runs 7 years deep, the most recent figure standing at $20.4 million for Q2 2024.

  • In Q2 2024, Short term Debt changed N/A year-over-year to $20.4 million; the TTM figure through Jun 2024 stood at $20.4 million (changed N/A YoY), while the FY2023 annual figure was $20.3 million, changed N/A from the prior year.
  • Short term Debt for Q2 2024 stood at $20.4 million, roughly flat from $20.4 million in the prior quarter.
  • The five-year high for Short term Debt was $56.4 million in Q2 2021, with the low at $3.2 million in Q3 2021.
  • The 4-year median for Short term Debt is $20.4 million (2024), against an average of $31.3 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.99 Bn 132.14 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 86.80 Bn 78.80 Bn 3.93 Bn
3 Argenx Se 65.38 Bn 60.19 Bn 1.37 Bn
4 Moderna 60.70 Bn 55.56 Bn 52.00 Mn
5 BeOne Medicines 42.22 Bn 37.12 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.67 Bn 28.36 Bn 992.69 Mn
7 BioNTech SE 28.45 Bn 10.06 Bn 668.28 Mn
8 Insmed 27.47 Bn 26.31 Bn 358.27 Mn
9 Royalty Pharma 27.21 Bn 26.37 Bn -
10 Protalix BioTherapeutics 193.97 Mn 153.31 Mn 12.13 Mn

Historic Data

Download Data
DateValue
Jun 30, 2024 20.42 Mn
Mar 31, 2024 20.42 Mn
Dec 31, 2023 20.25 Mn
Sep 30, 2023 20.19 Mn
Sep 30, 2021 3.24 Mn
Jun 30, 2021 56.36 Mn
Mar 31, 2021 55.37 Mn
Dec 31, 2020 54.43 Mn
Mar 31, 2018 5.93 Mn
Dec 31, 2017 5.92 Mn
Sep 30, 2017 5.91 Mn
Dec 31, 2016 53.87 Mn